Docoh
Loading...

ADCT Adc Therapeutics

Filed: 20 Nov 20, 7:12am
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2020

 

Commission File Number: 001-39071

 

ADC Therapeutics SA 

(Exact name of registrant as specified in its charter)

 

Biopôle

Route de la Corniche 3B 

1066 Epalinges 

Switzerland 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F

 Form 40-F 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 ADC Therapeutics SA
 
  
 By:/s/ Michael Forer

 Name:Michael Forer

 Title:Executive Vice President & General Counsel

  

Date: November 20, 2020

 

 

 

 

EXHIBIT INDEX

 

 

Exhibit NumberDescription
  
99.1Press Release dated November 20, 2020